Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s): QNTM

Healthcare

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

CSE:QNTM - Post by User

Quantum BioPharma Ltd > Im FSD Pharma supporter

<< Previous

Bullboard Posts

Next >>

Comment by Pyritetrapon Oct 29, 2021 4:21pm

37 Views

Post# 34066006

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Im FSD Pharma supporter

Pyritetrap wrote: Try this out

"FSD Pharma: A Rollup With Scattered, Uneconomical Cannabis Investments, 50-70% Downside

FSD Pharma’s founder, Thomas Fairfull, and director, Anthony Durkacz, have a history of value destruction. Durkacz had an average loss of 92% over 11 stocks in which he had involvement.

The company spent $8 million on listing fees, which is a head-scratcher, as it is multiple times larger than what comps spend.

Durkacz has received an astounding sum of over C$28.7 million total current value in cash and warrants for being both a director and broker for FSD.

FSD Pharma routinely announces investing in other small cannabis companies, but so far has shown little follow-through.

We have a price target on FSD of C$0.09 per share, which was its pre-RTO financing price less than a year ago."

https://seekingalpha.com/article/4234882-fsd-pharma-rollup-scattered-uneconomical-cannabis-investments-50minus-70-percent-downside